Skip to content

Interest Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$25.48M+3.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$6M-14.3%
uniQure logo
uniQureQURE
$5.23M+26.7%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$6.91M-14.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$4.36M+43.1%
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.97B+351%
Enterprise value$1.76B+368%
P/S263.9×+203×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s interest income?
Taysha Gene Therapies, Inc. (TSHA) reported interest income of $2.59M in Q1 2026.
How has Taysha Gene Therapies, Inc.'s interest income changed year-over-year?
Taysha Gene Therapies, Inc.'s interest income increased by 95.0% year-over-year, from $1.33M to $2.59M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.